Common use of Immediate Termination of Trial by Sponsor Clause in Contracts

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 11 contracts

Samples: Clinical Trial Agreement, Clinical Trial Agreement, Clinical Trial Agreement

AutoNDA by SimpleDocs

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator Provider for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 2 contracts

Samples: Clinical Trial Agreement, Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Trial Drug or Comparator Drug; or upon the occurrence of an event qualifying as a termination event under the Protocol.

Appears in 2 contracts

Samples: Clinical Trial Agreement, Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 2 contracts

Samples: Clinical Trial Agreement, Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.material

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon delivery of written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency RA actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency RA actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution Provider and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include but are not limited to failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution Provider and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; cause, which includes material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing well- being of Trial Subjects; or regulatory agency Regulatory Authority actions relating to the Trial or the Sponsor Drug or Comparator DrugAdditional Drugs or placebo.

Appears in 1 contract

Samples: Clinical Trial Agreement

AutoNDA by SimpleDocs

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing well being of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for Investigatorfor causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.zadavatelem. Zadavatel si vyhrazuje právo písemnou výpovědí zdravotnickému zařízení a hlavnímu zkoušejícímu klinické hodnocení okamžitě ukončit z důvodů, jako jsou nedostatečně rychlé zařazování subjektů klinického hodnocení k naplnění cílů

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing well being of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug Materials or Comparator Drug.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; cause, which includes material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing well-being of Trial Subjects; or regulatory agency Regulatory Authority actions relating to the Trial or the Sponsor Drug or Comparator DrugAdditional Drugs or placebo.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include but are not limited to the failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.regulatory

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing well being of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.

Appears in 1 contract

Samples: Clinical Trial Agreement

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing well being of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug.(2)

Appears in 1 contract

Samples: Clinical Trial Agreement

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!